These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 26838553)

  • 1. A case of type 1 diabetes mellitus with which localized insulin allergy was markedly alleviated by switching to insulin glulisine.
    Watanabe K; Kusunoki Y; Katsuno T; Nakae R; Matsuo T; Ochi F; Tokuda M; Akagami T; Miuchi M; Miyagawa J; Namba M
    Acta Diabetol; 2016 Oct; 53(5):845-8. PubMed ID: 26838553
    [No Abstract]   [Full Text] [Related]  

  • 2. A case of local delayed-type allergy to zinc-containing insulin as a cause of diabetic ketoacidosis in a patient with type 1 diabetes mellitus undergoing continuous subcutaneous insulin infusion.
    Nemoto KI; Ugi S; Ogaku S; Nakaizumi N; Kato T; Fuse K; Sekine O; Morino K; Tanaka T; Maegawa H
    Diabetol Int; 2016 Dec; 7(4):447-450. PubMed ID: 30603298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of insulin glulisine when given by continuous subcutaneous infusion using an external pump in patients with type 1 diabetes.
    Hoogma RP; Schumicki D
    Horm Metab Res; 2006 Jun; 38(6):429-33. PubMed ID: 16823727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin glulisine.
    Cox SL
    Drugs Today (Barc); 2005 Jul; 41(7):433-40. PubMed ID: 16193096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of switching to insulin glulisine from other rapid-acting insulin analogs in children with type 1 diabetes.
    Urakami T; Kuwabara R; Habu M; Okuno M; Suzuki J; Takahashi S
    J Diabetes Investig; 2015 Jan; 6(1):87-90. PubMed ID: 25621137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continuous subcutaneous insulin infusion allows tolerance induction and diabetes treatment in a type 1 diabetic child with insulin allergy.
    Hasselmann C; Pecquet C; Bismuth E; Raverdy C; Sola-Gazagnes A; Lobut JB; Carel JC; Tubiana-Rufi N
    Diabetes Metab; 2013 Apr; 39(2):174-7. PubMed ID: 23206896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Severe insulin allergy successfully treated with continuous subcutaneous insulin infusion.
    Fujikawa T; Imbe H; Date M; Go Y; Kitaoka H
    Diabetes Res Clin Pract; 2012 Aug; 97(2):e31-3. PubMed ID: 22609054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching to multiple daily injection therapy with glulisine improves glycaemic control, vascular damage and treatment satisfaction in basal insulin glargine-injected diabetic patients.
    Yanagisawa K; Ashihara J; Obara S; Wada N; Takeuchi M; Nishino Y; Maeda S; Ishibashi Y; Yamagishi S
    Diabetes Metab Res Rev; 2014 Nov; 30(8):693-700. PubMed ID: 24639403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of preprandial insulin glulisine versus insulin lispro in people with Type 2 diabetes over a 12-h period.
    Luzio S; Peter R; Dunseath GJ; Mustafa L; Owens DR
    Diabetes Res Clin Pract; 2008 Feb; 79(2):269-75. PubMed ID: 18164094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fields of application of continuous subcutaneous insulin infusion in the treatment of diabetes and implications in the use of rapid-acting insulin analogues.
    Pitocco D; Rizzi A; Scavone G; Tanese L; Zaccardi F; Manto A; Ghirlanda G
    Minerva Endocrinol; 2013 Sep; 38(3):321-8. PubMed ID: 24126552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin glulisine: an evaluation of its pharmacodynamic properties and clinical application.
    Helms KL; Kelley KW
    Ann Pharmacother; 2009 Apr; 43(4):658-68. PubMed ID: 19336657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A practical, clinical approach to the assessment and management of suspected insulin allergy.
    Jacquier J; Chik CL; Senior PA
    Diabet Med; 2013 Aug; 30(8):977-85. PubMed ID: 23601039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful management of allergy to the insulin excipient metacresol in a child with type 1 diabetes: a case report.
    Wheeler BJ; Taylor BJ
    J Med Case Rep; 2012 Aug; 6():263. PubMed ID: 22937994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generalized allergy due to zinc in insulin treated with zinc-free insulin.
    Ben Ammar I; Ksouri H; Trabelsi N; Mellouli F; Ben Mami F; Dakhli S; Achour A
    Acta Diabetol; 2012 Jun; 49(3):239-41. PubMed ID: 20963448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin glulisine in the treatment of allergy to rapid acting insulin and its rapid acting analogs.
    Mollar-Puchades MA; Villanueva IL
    Diabetes Res Clin Pract; 2009 Jan; 83(1):e21-2. PubMed ID: 19070911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advantage of premeal-injected insulin glulisine compared with regular human insulin in subjects with type 1 diabetes.
    Rave K; Klein O; Frick AD; Becker RH
    Diabetes Care; 2006 Aug; 29(8):1812-7. PubMed ID: 16873785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advantage of insulin glulisine over regular insulin in patients with type 2 diabetes and severe renal insufficiency.
    Urata H; Mori K; Emoto M; Yamazaki Y; Motoyama K; Morioka T; Fukumoto S; Koyama H; Shoji T; Ishimura E; Inaba M
    J Ren Nutr; 2015 Mar; 25(2):129-34. PubMed ID: 25238698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety results from OCAPI: a European Observational Cohort Study of insulin glulisine-treated children aged 6-12 years with type 1 diabetes.
    Konstantinova M; Loizeau V; Pilorget V; Cali A; Danne T
    Exp Clin Endocrinol Diabetes; 2014 Oct; 122(9):523-7. PubMed ID: 25054310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin glulisine: a faster onset of action compared with insulin lispro.
    Heise T; Nosek L; Spitzer H; Heinemann L; Niemöller E; Frick AD; Becker RH
    Diabetes Obes Metab; 2007 Sep; 9(5):746-53. PubMed ID: 17593235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two single-dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs.
    Lankisch MR; Ferlinz KC; Leahy JL; Scherbaum WA;
    Diabetes Obes Metab; 2008 Dec; 10(12):1178-85. PubMed ID: 19040645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.